Interleukin 6 as a key regulator of muscle mass during cachexia - Wikidata - wikimedia - TriplyDB

Interleukin 6 as a key regulator of muscle mass during cachexia

Interleukin 6 as a key regulator of muscle mass during cachexia

http://www.wikidata.org/entity/Q34727530

about

B-Cell Activating Factor as a Cancer Biomarker and Its Implications in Cancer-Related Cachexia Interleukin-6 myokine signaling in skeletal muscle: a double-edged sword?IL-6 and IGF-1 Signaling Within and Between Muscle and Bone: How Important is the mTOR Pathway for Bone Metabolism?Depletion of white adipose tissue in cancer cachexia syndrome is associated with inflammatory signaling and disrupted circadian regulation Molecular pathways leading to loss of skeletal muscle mass in cancer cachexia--can findings from animal models be translated to humans?Molecular Mechanisms of Obesity-Induced Osteoporosis and Muscle Atrophy Reactive Oxygen Species/Nitric Oxide Mediated Inter-Organ Communication in Skeletal Muscle Wasting Diseases.Cachectic skeletal muscle response to a novel bout of low-frequency stimulation Substrate and strain alter the muscle-derived mesenchymal stem cell secretome to promote myogenesis.The regulation of skeletal muscle protein turnover during the progression of cancer cachexia in the Apc(Min/+) mouse.Muscle oxidative capacity during IL-6-dependent cancer cachexia.Cancer cachexia, mechanism and treatment Sex differences in the relationship of IL-6 signaling to cancer cachexia progression Preserved muscle oxidative metabolic phenotype in newly diagnosed non-small cell lung cancer cachexia.Tocilizumab for the treatment of rheumatoid arthritis and other systemic autoimmune diseases: current perspectives and future directions.The effect of exercise on IL-6-induced cachexia in the Apc ( Min/+) mouse.JAK/STAT3 pathway inhibition blocks skeletal muscle wasting downstream of IL-6 and in experimental cancer cachexia.IL-6 regulation on skeletal muscle mitochondrial remodeling during cancer cachexia in the ApcMin/+ mouse.Sarcopenia, obesity, and natural killer cell immune senescence in aging: altered cytokine levels as a common mechanism Lewis lung carcinoma regulation of mechanical stretch-induced protein synthesis in cultured myotubes.Oral resveratrol therapy inhibits cancer-induced skeletal muscle and cardiac atrophy in vivo The emerging role of skeletal muscle oxidative metabolism as a biological target and cellular regulator of cancer-induced muscle wasting TWEAK promotes exercise intolerance by decreasing skeletal muscle oxidative phosphorylation capacity.Characterization of the male ApcMin/+ mouse as a hypogonadism model related to cancer cachexia.Regulation of protein degradation pathways by amino acids and insulin in skeletal muscle of neonatal pigs.Short-term pyrrolidine dithiocarbamate administration attenuates cachexia-induced alterations to muscle and liver in ApcMin/+ mice.The role of vitamin D in skeletal and cardiac muscle function Serum cytokines associated with severity and complications of kala-azar.IL-6/IL-6 receptor system and its role in physiological and pathological conditions.Immunotherapeutic implication of IL-6 blockade.The role of interleukin-6 in the evolution of ovarian cancer: clinical and prognostic implications--a review.Disruption of MEF2C signaling and loss of sarcomeric and mitochondrial integrity in cancer-induced skeletal muscle wasting Muscle wasting as main evidence of energy impairment in cancer cachexia: future therapeutic approaches.Pantoprazole blocks the JAK2/STAT3 pathway to alleviate skeletal muscle wasting in cancer cachexia by inhibiting inflammatory response.An Immune-Modulating Diet in Combination with Chemotherapy Prevents Cancer Cachexia by Attenuating Systemic Inflammation in Colon 26 Tumor-Bearing Mice.IL-6 impairs myogenic differentiation by downmodulation of p90RSK/eEF2 and mTOR/p70S6K axes, without affecting AKT activity MG132-mediated inhibition of the ubiquitin-proteasome pathway ameliorates cancer cachexia.Inhibitory effects of IL-6 on IGF-1 activity in skeletal myoblasts could be mediated by the activation of SOCS-3.Lipopolysaccharide (LPS) and tumor necrosis factor alpha (TNFα) blunt the response of Neuropeptide Y/Agouti-related peptide (NPY/AgRP) glucose inhibited (GI) neurons to decreased glucose.Increased levels of interleukin-6 exacerbate the dystrophic phenotype in mdx mice.

P2860

Q26784444-520B8588-AACC-4A58-80FD-A422406CD8CE Q26866208-BB0C291F-8DF8-43F8-A4C9-C0D89CEBC19F Q27024703-0970777D-0A90-4156-B4CB-8659CE8AB326 Q27312755-A743AABD-AC66-48A6-AE5F-5C9D3957259C Q28068034-7899B05E-6063-46E8-AF38-8C6AE9E53861 Q28072006-A0A83863-981C-4035-A9B4-7A828FF4323E Q30275433-2EAB1DE4-6EA5-4C97-9B13-F7E837C22397 Q33673314-0C5D3BA6-4242-49BB-91EA-ACAA86A7BDA3 Q33900539-95BB2B05-A41C-4F9D-A236-560B0144DD60 Q34031423-EB03A14F-990F-4D35-9B34-C5710F8CFD3C Q34598672-EB8C2ED8-3E94-4DCB-98E0-5CB68F88FF57 Q34669440-16BEA115-8F89-4F65-8E0E-039E29036C7D Q35214154-BC21F5EA-E90C-4CE8-ABB2-284C0B9B4C99 Q35690207-A1B86A42-4225-4A0B-9211-7C1E359EFE59 Q35724900-5344AC35-BAB3-4FBC-85DE-28D712284534 Q36028206-8BD8FA5F-8B63-4A3D-B3E0-FACACD0FFF68 Q36176015-7B22163A-2A06-40B1-84AC-4D0383BFCD66 Q36200582-27AFDAB4-1924-4452-84D6-BAD0190C059E Q36288649-B79E6BAB-FE28-46FD-9D24-7F41E93E8518 Q36422693-B4049224-CC91-47D3-AE41-5D07980367B0 Q36756845-0EB34D53-7053-46DA-AE80-B335550E0F8E Q36901945-10B751B1-D89A-41AE-82F7-1AE1409451FF Q37014194-C0431BA8-A2A6-4EE5-879D-55AB350E6A93 Q37392800-0C96A5B9-2FD7-47B2-A6EF-2D98A50ABEDA Q37514534-A1F7CA39-0C9A-4C9E-A17F-D7ACF3188ADF Q37644886-A63F1DF0-FD36-4337-8DD9-D15FF263B64B Q37715719-99209478-D03F-40F2-AD22-88C843F45C4B Q37726527-EFF430C5-81E8-4217-B27D-932ADD838CFF Q37949664-71C2E39D-4794-4440-9B10-C7F6E1E7C51A Q37965754-A29A9F35-CFD8-4ADC-B3D6-F04E9AF69D0C Q38140767-CA555D99-CFBC-4C17-9EED-418C3C179F1B Q38434245-5857A38A-49CD-4D3A-9C2A-37DDAC872C5D Q38587970-C0866550-6EC7-42D8-8067-5D284CF4E7CA Q38704047-AAA82A6A-6B3E-4D5B-B2EA-78237F5DC64F Q38857963-2EE17A50-7CAD-4953-948F-C0F7C7501AE2 Q38981101-518F7FC5-D326-46A6-B18D-20A4F41990ED Q39174681-ED1C79E1-6C25-4EAB-89B9-424E1AECB1EE Q39451520-77051209-C68B-4467-95B7-2ACB4ACA68C6 Q39544008-735FBF1F-69F4-4BD8-BA55-5E9096F3978F Q41045084-A025E7A5-28DD-443D-BCD5-1C1E5BED89EA

P2860

Interleukin 6 as a key regulator of muscle mass during cachexia

http://www.wikidata.org/entity/Q34727530

description

2010 nî lūn-bûn

@nan

2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

name

Interleukin 6 as a key regulator of muscle mass during cachexia

@ast

Interleukin 6 as a key regulator of muscle mass during cachexia

@en

Interleukin 6 as a key regulator of muscle mass during cachexia

@nl

type

label

Interleukin 6 as a key regulator of muscle mass during cachexia

@ast

Interleukin 6 as a key regulator of muscle mass during cachexia

@en

Interleukin 6 as a key regulator of muscle mass during cachexia

@nl

prefLabel

Interleukin 6 as a key regulator of muscle mass during cachexia

@ast

Interleukin 6 as a key regulator of muscle mass during cachexia

@en

Interleukin 6 as a key regulator of muscle mass during cachexia

@nl

P1433

Q34727530-766ACB60-B270-46EF-95FF-716E8922726B

P1476

Q34727530-D0806E1B-F940-41C2-BC31-B70C7A9AEAE5

P2093

Q34727530-DFA22EDA-A88C-4353-B233-74397AB53332

P2860

Q34727530-0235AD25-054C-458C-8408-5437EA5B6F0B

Q34727530-0B8818F8-602F-40FC-89EC-4703CD671927

Q34727530-2B6A3DD0-F7B2-4210-BA2B-6FF64FD42E26

Q34727530-31931A9A-84A2-4AB3-AD51-D66F9B5D6AF6

Q34727530-327D13C5-102B-4EAF-A751-B0AAE34A441E

Q34727530-39D4E5BE-380B-4991-8B8B-0861BF05461D

Q34727530-518E938D-66CC-40F7-B51C-FB8170331B3C

Q34727530-58751DDF-9584-4122-905D-535E64C7CAD2

Q34727530-59908181-F944-4296-92A5-978EF3AFF2AB

Q34727530-5B5B9A93-02DB-456D-AD0E-87EB415129A9

P304

Q34727530-88535482-441A-4F77-8300-92C830388B27

P31

Q34727530-8F250EA8-DD7D-4478-B8F5-7C3277327A00

P356

Q34727530-91D57337-B9CB-4F97-B0E4-131DE6B72D51

P433

Q34727530-D66A37FA-C7E1-4B24-A378-6E941FE93747

P478

Q34727530-9CF47A35-2069-4DB6-B2F6-AE61CB0EFE0B

P50

Q34727530-2EC37EA2-2789-40FB-A71B-6F2252B463F2

P577

Q34727530-B3612421-391D-4800-BF9E-6299D1245FBB

P698

Q34727530-1020C6FF-4CC3-4591-BEA2-0A4AC23E557E

P921

Q34727530-7d71b5bd-9408-408e-8ca8-7edd602cba17

P932

Q34727530-169592B2-F784-4027-AC0A-B385A274E112

P356

JES.0B013E3181F44F11

P1433

Exercise and Sport Sciences Reviews

P1476

Interleukin 6 as a key regulator of muscle mass during cachexia

@en

P2093

Kristen A Baltgalvis

http://www.w3.org/2001/XMLSchema#string

P2860

Principles of interleukin (IL)-6-type cytokine signalling and its regulation

A trauma-like elevation of plasma cytokines in humans in response to treadmill running

Consensus definition of sarcopenia, cachexia and pre-cachexia: joint document elaborated by Special Interest Groups (SIG) "cachexia-anorexia in chronic wasting diseases" and "nutrition in geriatrics"

Skeletal muscle growth in young rats is inhibited by chronic exposure to IL-6 but preserved by concurrent voluntary endurance exercise

Interleukin-6 and cachexia in ApcMin/+ mice

Muscle wasting and interleukin-6-induced atrogin-I expression in the cachectic Apc ( Min/+ ) mouse

The interaction of a high-fat diet and regular moderate intensity exercise on intestinal polyp development in Apc Min/+ mice

Mechanisms of cancer cachexia.

Activity level, apoptosis, and development of cachexia in Apc(Min/+) mice.

Interleukin-6 causes myocardial failure and skeletal muscle atrophy in rats.

P304

168-176

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/JES.0B013E3181F44F11

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

38

http://www.w3.org/2001/XMLSchema#string

P50

James A. Carson

P577

2010-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20871233

http://www.w3.org/2001/XMLSchema#string

P921

P932

3065300

http://www.w3.org/2001/XMLSchema#string